These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 35214685)

  • 1. Virus-like Particles as Preventive and Therapeutic Cancer Vaccines.
    Tornesello AL; Tagliamonte M; Buonaguro FM; Tornesello ML; Buonaguro L
    Vaccines (Basel); 2022 Feb; 10(2):. PubMed ID: 35214685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing Chimeric Virus-like Particle-based Vaccines for Human Papillomavirus and HIV: Lessons Learned.
    Eto Y; Saubi N; Ferrer P; Joseph J
    AIDS Rev; 2019; 21(4):218-232. PubMed ID: 31834327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-like Particle Vaccines and Platforms for Vaccine Development.
    Kheirvari M; Liu H; Tumban E
    Viruses; 2023 May; 15(5):. PubMed ID: 37243195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A virus-like particle-based Epstein-Barr virus vaccine.
    Ruiss R; Jochum S; Wanner G; Reisbach G; Hammerschmidt W; Zeidler R
    J Virol; 2011 Dec; 85(24):13105-13. PubMed ID: 21994444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
    Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
    Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
    [No Abstract]   [Full Text] [Related]  

  • 6. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virus like particles as a platform for cancer vaccine development.
    Ong HK; Tan WS; Ho KL
    PeerJ; 2017; 5():e4053. PubMed ID: 29158984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy.
    Ruzzi F; Semprini MS; Scalambra L; Palladini A; Angelicola S; Cappello C; Pittino OM; Nanni P; Lollini PL
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity.
    Pascual E; Mata CP; Gómez-Blanco J; Moreno N; Bárcena J; Blanco E; Rodríguez-Frandsen A; Nieto A; Carrascosa JL; Castón JR
    J Virol; 2015 Mar; 89(5):2563-74. PubMed ID: 25520499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice.
    Perez EM; Foley J; Tison T; Silva R; Ogembo JG
    Oncotarget; 2017 Mar; 8(12):19255-19273. PubMed ID: 27926486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
    Hyakumura M; Walsh R; Thaysen-Andersen M; Kingston NJ; La M; Lu L; Lovrecz G; Packer NH; Locarnini S; Netter HJ
    J Virol; 2015 Nov; 89(22):11312-22. PubMed ID: 26339047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity.
    Joe CCD; Chatterjee S; Lovrecz G; Adams TE; Thaysen-Andersen M; Walsh R; Locarnini SA; Smooker P; Netter HJ
    Vaccine; 2020 May; 38(22):3892-3901. PubMed ID: 32284273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen.
    Pleckaityte M; Bremer CM; Gedvilaite A; Kucinskaite-Kodze I; Glebe D; Zvirbliene A
    BMC Biotechnol; 2015 Sep; 15():85. PubMed ID: 26370129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric HBcAg virus-like particles presenting a HPV 16 E7 epitope significantly suppressed tumor progression through preventive or therapeutic immunization in a TC-1-grafted mouse model.
    Chu X; Li Y; Long Q; Xia Y; Yao Y; Sun W; Huang W; Yang X; Liu C; Ma Y
    Int J Nanomedicine; 2016; 11():2417-29. PubMed ID: 27313455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT; Boo I; Drummer HE; Netter HJ
    Antivir Ther; 2007; 12(4):477-87. PubMed ID: 17668556
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Virus-Like Particles of Prawn Nodavirus Displaying Hepatitis B Virus Immunodominant Region: Biophysical Properties and Cytokine Response.
    Ninyio NN; Ho KL; Yong CY; Chee HY; Hamid M; Ong HK; Mariatulqabtiah AR; Tan WS
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.
    Zepeda-Cervantes J; Ramírez-Jarquín JO; Vaca L
    Front Immunol; 2020; 11():1100. PubMed ID: 32582186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status and future directions of fish vaccines employing virus-like particles.
    Jeong KH; Kim HJ; Kim HJ
    Fish Shellfish Immunol; 2020 May; 100():49-57. PubMed ID: 32130976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disassembly and reassembly of human papillomavirus virus-like particles produces more virion-like antibody reactivity.
    Zhao Q; Modis Y; High K; Towne V; Meng Y; Wang Y; Alexandroff J; Brown M; Carragher B; Potter CS; Abraham D; Wohlpart D; Kosinski M; Washabaugh MW; Sitrin RD
    Virol J; 2012 Feb; 9():52. PubMed ID: 22356831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Epstein-Barr virus mutant produces immunogenic defective particles devoid of viral DNA.
    Pavlova S; Feederle R; Gärtner K; Fuchs W; Granzow H; Delecluse HJ
    J Virol; 2013 Feb; 87(4):2011-22. PubMed ID: 23236073
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.